Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $25.00 target price on the stock.

Several other brokerages also recently weighed in on HUMA. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Humacyte in a research note on Wednesday, November 13th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. BTIG Research restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. TD Cowen reiterated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, Benchmark restated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Humacyte presently has a consensus rating of “Buy” and a consensus price target of $13.00.

Humacyte Stock Performance

Humacyte stock opened at $4.52 on Thursday. Humacyte has a fifty-two week low of $2.43 and a fifty-two week high of $9.97. The company has a market capitalization of $568.89 million, a price-to-earnings ratio of -3.35 and a beta of 1.47. The stock has a fifty day moving average of $5.31 and a two-hundred day moving average of $6.19. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10.

Insider Transactions at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Laura E. Niklason sold 277,090 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total value of $1,792,772.30. Following the transaction, the chief executive officer now owns 4,029,374 shares in the company, valued at $26,070,049.78. This trade represents a 6.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,584,153 shares of company stock valued at $13,476,796. 11.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC boosted its stake in Humacyte by 177.6% in the third quarter. Barclays PLC now owns 236,742 shares of the company’s stock valued at $1,288,000 after acquiring an additional 151,458 shares during the period. Geode Capital Management LLC grew its stake in Humacyte by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock worth $11,101,000 after buying an additional 179,120 shares during the last quarter. XTX Topco Ltd increased its position in Humacyte by 48.8% in the third quarter. XTX Topco Ltd now owns 34,049 shares of the company’s stock worth $185,000 after buying an additional 11,172 shares during the period. Insigneo Advisory Services LLC bought a new stake in Humacyte in the third quarter valued at $109,000. Finally, Wellington Management Group LLP increased its holdings in shares of Humacyte by 30.9% in the 3rd quarter. Wellington Management Group LLP now owns 254,411 shares of the company’s stock worth $1,384,000 after acquiring an additional 60,087 shares during the period. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.